

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)  
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2020  
FOR  
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

**BRITISH NUCLEAR MEDICINE SOCIETY**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2020**

	<b>Page</b>
<b>Report of the Trustees</b>	<b>1 to 3</b>
<b>Independent Examiner's Report</b>	<b>4</b>
<b>Statement of Financial Activities</b>	<b>5</b>
<b>Balance Sheet</b>	<b>6</b>
<b>Notes to the Financial Statements</b>	<b>7 to 12</b>

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

**Significant activities**

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

**Public benefit**

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**ACHIEVEMENT AND PERFORMANCE****Charitable activities**

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	<b>Liverpool (cancelled) £</b>	<b>Virtual £</b>	<b>Total £</b>
<b>Income</b>			
Commercial exhibition income	-	4,500	4,500
Annual conference delegate registration fees	-	5,900	5,900
	-	10,400	10,400
Less: Scientific meeting expenses	489	-7,307	-7,917
Surplus / (deficit)	-489	3,093	2,484

**Fundraising activities**

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

**Covid-19 Pandemic**

The onset of the Pandemic caused significant disruption to the society's operations and scientific meetings.

The charity has introduced a few changes to our working practices to safeguard our employees and trustees. These include, closing the head office and moving to home working. Reducing the number of staff from three to two.

The charity made the difficult decision to cancel our annual spring meeting in Liverpool and convert our move our autumn meeting in Leeds to an online meeting.

We are pleased that membership numbers have been steady during the year and that most of the costs scientific meetings that were cancelled, were recovered by the charity for future meetings.

The ongoing pandemic brings continued uncertainty to the wider economy and our own operations. However, the trustees are confident the charity is well placed to deal with these challenges.

**FUTURE PLANS**

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

**STRUCTURE, GOVERNANCE AND MANAGEMENT****Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REFERENCE AND ADMINISTRATIVE DETAILS****Registered Company number**

08082786 (England and Wales)

**Registered Charity number**

1150234

**Registered office**

Royal College of Physicians  
11 St Andrews Place  
Regents Park  
London  
London  
NW1 4LE

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**Trustees**

Mrs J Croasdale Radiopharmacist  
Dr R Graham Radiologist  
Dr S Redman Clinical Scientist  
Mr C S Kalirai Nuclear Medicine Physicist  
Dr J R Buscombe Nuclear Medicine Physician  
Mr N Gulliver Nuclear Medicine Technologist (resigned 23.9.20)  
Dr Y Du Nuclear Medicine Physician (resigned 23.9.20)  
Dr F X Sundram Physician  
Dr A G Irwin Clinical Scientist  
Mr C Mayes Trustee (appointed 23.9.20)  
Dr A Parthipun Trustee (appointed 23.9.20)

**Independent Examiner**

E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

Approved by order of the board of trustees on 23 March 2021 and signed on its behalf by:

Dr J R Buscombe - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
BRITISH NUCLEAR MEDICINE SOCIETY**

**Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas  
Senior Statutory Auditor  
E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

23 March 2021

**BRITISH NUCLEAR MEDICINE SOCIETY**  
**STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 DECEMBER 2020**

	Notes	Unrestricted fund £	Restricted fund £	2020 Total funds £	2019 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		-	-	-	42
Other trading activities	2	82,144	-	82,144	272,789
Investment income	3	1,291	13	1,304	1,839
Other income		69,981	-	69,981	51,512
<b>Total</b>		<u>153,416</u>	<u>13</u>	<u>153,429</u>	<u>326,182</u>
<b>EXPENDITURE ON</b>					
Raising funds	4	<u>170,544</u>	<u>-</u>	<u>170,544</u>	<u>297,129</u>
<b>NET INCOME/(EXPENDITURE)</b>		<u>(17,128)</u>	<u>13</u>	<u>(17,115)</u>	<u>29,053</u>
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<u>328,375</u>	<u>14,349</u>	<u>342,724</u>	<u>313,671</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><u>311,247</u></u>	<u><u>14,362</u></u>	<u><u>325,609</u></u>	<u><u>342,724</u></u>

The notes form part of these financial statements

**BALANCE SHEET**  
**31 DECEMBER 2020**

	Notes	Unrestricted fund £	Restricted fund £	2020 Total funds £	2019 Total funds £
<b>FIXED ASSETS</b>					
Tangible assets	9	6,724	-	6,724	8,614
<b>CURRENT ASSETS</b>					
Debtors	10	151,916	-	151,916	156,905
Cash at bank		218,350	14,362	232,712	271,401
		<u>370,266</u>	<u>14,362</u>	<u>384,628</u>	<u>428,306</u>
<b>CREDITORS</b>					
Amounts falling due within one year	11	(65,743)	-	(65,743)	(94,196)
<b>NET CURRENT ASSETS</b>		<u>304,523</u>	<u>14,362</u>	<u>318,885</u>	<u>334,110</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>311,247</u>	<u>14,362</u>	<u>325,609</u>	<u>342,724</u>
<b>NET ASSETS</b>		<u>311,247</u>	<u>14,362</u>	<u>325,609</u>	<u>342,724</u>
<b>FUNDS</b>	12				
Unrestricted funds				311,247	328,375
Restricted funds				14,362	14,349
<b>TOTAL FUNDS</b>				<u>325,609</u>	<u>342,724</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 23 March 2021 and were signed on its behalf by:

Dr J R Buscombe - Trustee

**BRITISH NUCLEAR MEDICINE SOCIETY**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2020**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Pension costs and other post-retirement benefits**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**2. OTHER TRADING ACTIVITIES**

	2020	2019
	£	£
Commercial exhibition income	4,500	111,313
Annual conference delegate registration fees	5,900	88,295
Commission received	856	870
Royalties received	70,617	68,775
Other project income	271	3,536
	<hr/>	<hr/>
	82,144	272,789
	<hr/>	<hr/>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**3. INVESTMENT INCOME**

	2020	2019
	£	£
Deposit account interest	<u>1,304</u>	<u>1,839</u>

**4. RAISING FUNDS**

**Raising donations and legacies**

	2020	2019
	£	£
Support costs	<u>114,832</u>	<u>104,235</u>

**5. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2020	2019
	£	£
Other assurance services	5,000	3,150
Depreciation - owned assets	3,446	4,238
Deficit on disposal of fixed assets	<u>248</u>	<u>-</u>

**6. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

**Trustees' expenses**

Expenses of £1,355 (2019: £6,135) were paid to the trustees during the year.

**7. STAFF COSTS**

The average monthly number of employees during the year was as follows:

	2020	2019
	3	3
Administrative	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	42	-	42
Other trading activities	272,789	-	272,789
Investment income	1,811	28	1,839
Other income	<u>51,512</u>	<u>-</u>	<u>51,512</u>
<b>Total</b>	326,154	28	326,182
<b>EXPENDITURE ON</b>			
Raising funds	<u>297,129</u>	<u>-</u>	<u>297,129</u>
<b>NET INCOME</b>	29,025	28	29,053

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	299,350	14,321	313,671
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>328,375</u>	<u>14,349</u>	<u>342,724</u>

**9. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2020	789	30,944	31,733
Additions	-	1,883	1,883
Disposals	-	(2,725)	(2,725)
At 31 December 2020	<u>789</u>	<u>30,102</u>	<u>30,891</u>
<b>DEPRECIATION</b>			
At 1 January 2020	579	22,540	23,119
Charge for year	32	3,414	3,446
Eliminated on disposal	-	(2,398)	(2,398)
At 31 December 2020	<u>611</u>	<u>23,556</u>	<u>24,167</u>
<b>NET BOOK VALUE</b>			
At 31 December 2020	<u>178</u>	<u>6,546</u>	<u>6,724</u>
At 31 December 2019	<u>210</u>	<u>8,404</u>	<u>8,614</u>

**10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020 £	2019 £
Trade debtors	2,773	65,351
Other debtors	60,015	19,310
VAT	15,067	-
Prepayments and accrued income	74,061	72,244
	<u>151,916</u>	<u>156,905</u>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020 £	2019 £
Trade creditors	51,736	19,074
Social security and other taxes	66	-
VAT	-	7,119
Other creditors	10,941	65,003
Accrued expenses	3,000	3,000
	<u>65,743</u>	<u>94,196</u>

**12. MOVEMENT IN FUNDS**

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
<b>Unrestricted funds</b>			
General fund	328,375	(17,128)	311,247
<b>Restricted funds</b>			
Ross Breen Fund	14,349	13	14,362
	<u>342,724</u>	<u>(17,115)</u>	<u>325,609</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	153,416	(170,544)	(17,128)
<b>Restricted funds</b>			
Ross Breen Fund	13	-	13
	<u>153,429</u>	<u>(170,544)</u>	<u>(17,115)</u>

**Comparatives for movement in funds**

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
<b>Unrestricted funds</b>			
General fund	299,350	29,025	328,375
<b>Restricted funds</b>			
Ross Breen Fund	14,321	28	14,349
	<u>313,671</u>	<u>29,053</u>	<u>342,724</u>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**12. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	326,154	(297,129)	29,025
<b>Restricted funds</b>			
Ross Breen Fund	28	-	28
<b>TOTAL FUNDS</b>	<u>326,182</u>	<u>(297,129)</u>	<u>29,053</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.19 £	Net movement in funds £	At 31.12.20 £
<b>Unrestricted funds</b>			
General fund	299,350	11,897	311,247
<b>Restricted funds</b>			
Ross Breen Fund	14,321	41	14,362
<b>TOTAL FUNDS</b>	<u>313,671</u>	<u>11,938</u>	<u>325,609</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	479,570	(467,673)	11,897
<b>Restricted funds</b>			
Ross Breen Fund	41	-	41
<b>TOTAL FUNDS</b>	<u>479,611</u>	<u>(467,673)</u>	<u>11,938</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**13. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2020.